Cargando…
SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement
Monoclonal antibodies (mAbs) are emerging as safe and effective therapeutics against SARS-CoV-2. However, variant strains of SARS-CoV-2 have evolved, with early studies showing that some mAbs may not sustain their efficacy in the face of escape mutants. Also, from the onset of the COVID-19 pandemic,...
Autores principales: | Wang, Ying-Ting, Allen, Robert D., Kim, Kenneth, Shafee, Norazizah, Gonzalez, Andrew J., Nguyen, Michael N., Valentine, Kristen M., Cao, Xia, Lu, Lucy, Pai, Chin-I, Johnson, Sachi, Kerwin, Lisa, Zhou, Heyue, Zhang, Yanliang, Shresta, Sujan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498781/ https://www.ncbi.nlm.nih.gov/pubmed/34634289 http://dx.doi.org/10.1016/j.antiviral.2021.105185 |
Ejemplares similares
-
Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021) -
An in vitro methodology for discovering broadly-neutralizing monoclonal antibodies
por: Ahmadi, Shirin, et al.
Publicado: (2020) -
Broad neutralization of SARS-related viruses by human monoclonal antibodies
por: Wec, Anna Z., et al.
Publicado: (2020) -
Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015) -
Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
por: McCoy, Laura E., et al.
Publicado: (2015)